The DePinho laboratory now shows that multiple RTKs are co-activated in untreated GBM and combinations of RTK inhibitors, but not single agents, may be used as a strategy for their treatment.

I study and characterize the response to KRAS G12C, SOS1 and SHP2 inhibitors alone or in combination with receptor tyrosine kinase (RTK) or MEK inhibitors in different tumor types to determine the ...